Takeda’s AI Strategy: ‘This Is More Than About Speed And Cost’
Scrip spoke with Takeda chief scientific officer Christopher Arendt about how the company is integrating artificial intelligence across its research functions and seeing early proof points from its AI collaborations with a focus on delivering high-quality molecules faster.
Scrip - July 2, 2026

Device Data Still Missing From FDA’s AEMS Dashboard After May Deadline
While the FDA initially planned to integrate device data into the unified AEMS database by the end of May, the timeline is currently up in the air. Integration of AEMS with the medical device reporting system is expected in late July and changes to the public-facing portal are still to come.
Medtech Insight - July 1, 2026

Top Medtechs’ Annual Average Growth Hits 8.5%
A handful of ranking changes among medtech’s topmost global tier in an industry showing healthy growth were reflected in In Vivo’s US dollar-rankings for calendar 2025.
Medtech Insight - July 1, 2026

Zimmer Biomet Adds Non-Opioid Pain Device With Iovera Acquisition
Zimmer Biomet is acquiring Pacira's iovera cryoneurolysis platform for up to $140m, adding a drug-free nerve-blocking device to its orthopedic portfolio.
Medtech Insight - July 1, 2026

Shift In US Kratom Policy To Scheduling 7-OH, Similar Derivatives Reaches DEA Notice
DEA files intent to temporarily place 7-OH and along with three other kratom derivatives into CSA Schedule after HHS Secretary Kennedy prioritized research leading to finding that the four substances have no accepted medical use and high potential for abuse.
HBW Insight - July 2, 2026

Hybio Submits Paragraph IV Challenge For Its Generic Tirzepatide Pen
The ranks of generic rivals to Mounjaro and Zepbound are filling up, with Hybio Pharmaceutical, Adalvo and Amneal announcing their successful submissions.
Generics Bulletin - July 1, 2026

Orion Partners With Shilpa On Opdivo Biosimilar In Europe
Orion Pharma and Shilpa Biologicals build on their existing partnership with a fresh nivolumab biosimilar deal.
Generics Bulletin - July 1, 2026

‘We Don’t See Coherence In This Strategy’ – Medicines for Europe Leaders On The EU Biotech Act
At Medicines for Europe’s legal affairs conference, the mood was broadly receptive to the revised EU pharma package – but far frostier towards the EU Biotech Act’s proposed 12-month SPC extension. Sergio Napolitano and Adrian van den Hoven explained why the latter proposal must be removed.
Generics Bulletin - July 1, 2026

Viatris Eyes First IgAN-Specific Budesonide Therapy In Japan
Viatris’ partnered targeted-release budesonide has hit the primary endpoint in a 39-patient Japanese Phase III IgAN study, setting up a planned NDA submission by the end of 2026.
Generics Bulletin - July 1, 2026

Canada’s Generic GLP-1 Momentum Spreads To Weight Loss
Apotex’s Sevmia approval gives Canada its first generic Wegovy rival, widening the country’s early lead in off-patent semaglutide as more GLP-1 filings await Health Canada decisions.
Generics Bulletin - July 1, 2026

What’s Next? Five Things To Look Out For In July
Generics Bulletin previews the most noteworthy and anticipated events for July 2026.
Generics Bulletin - July 1, 2026

How Neurology M&A Has Evolved Over The Last Decade: Upfronts, Multiples And Mechanisms
An analysis of 75 disclosed acquisitions in the neurology sector totaling over $180bn reveals widening deal values, structurally shifting indication preferences, compressing return multiples, and a new dataset linking acquisition stage and price to post-acquisition clinical outcomes.
In Vivo - July 1, 2026